Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
Tuspetinib in combination with venetoclax and azacitidine showed promising clinical safety and antileukemic activity in AML.
Presented preclinical model data show significant efficacy against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Mice treated with CLK3 TCR9-T cells had a significantly lower tumor burden than those who received control treatments.
Kelly Chien, MD, discusses how disparities in access to care, resources, and molecular testing impact outcomes in AML.
CR1-02 was well-tolerated and led to stable disease in patients with relapsed or refractory AML.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
The investigational small molecule enzomenib has received FDA Orphan Drug and Fast Track designations in AML.
GPC-100 is a a small molecule CXCR4 inhibitor that showed promising preclinical activity in combination with cytarabine.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.